Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leuk... - PubMed - NCBI1 selected item: 29411857Br J Haematol. 2018 Feb 7. doi: 10.1111/bjh.15123. [Epub ahead of print]Ishida T1, Jo T2, Takemoto S3, Suzushima H4, Suehiro Y5, Choi I5, Yoshimitsu M6, Saburi Y7, Nosaka K8, Utsunomiya A9, Kobayashi Y10, Yamamoto K11, Fujiwara H12, Ishitsuka K13, Yoshida S14, Taira N15, Imada K16, Kato K17, Moriuchi Y18, Yoshimura K19, Takahashi T20, Tobinai K10, Ueda R21.Department of Haematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.Department of Haematology, National Hospital Organization Kyushu Cancer Centre Hospital, Fukuoka, Japan.Department of Haematology, Rheumatology and Infectious Disease, Kumamoto University Hospital, Kumamoto, Japan.Department of Haematology, Imamura General Hospital, Kagoshima, Japan.Department of Haematology and Cell Therapy, Aichi Cancer Centre Hospital, Nagoya, Aichi, Japan.Department of Haematology, Clinical Immunology and Infectious Disease, Ehime University Graduate School of Medicine, Ehime, Japan.Division of Medical Oncology, Haematology, and Infectious Diseases, Department of Medicine, Fukuoka University Hospital, Fukuoka, Japan.Department of Haematology, National Hospital Organization Nagasaki Medical Centre, Omura, Nagasaki, Japan.Department of Haematology, Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan.Department of Haematology, Sasebo City General Hospital, Sasebo, Nagasaki, Japan.Innovative Clinical Research Centre, Kanazawa University, Kanazawa, Japan.adult T-cell leukaemia-lymphoma; follow-up; mogamulizumab
